Form 4: NeueHealth Executive Tomas Orozco Receives Stock Grants Following Shareholder Approval

EVP Tomas Orozco of NeueHealth, Inc. reports the acquisition of restricted stock units following shareholder approval of an amendment to the company's incentive plan.

Summary

• Tomas Orozco, EVP of Consumer Care at NeueHealth, Inc., filed a Form 4 on May 6, 2024, reporting changes in beneficial ownership.
• The report details the acquisition of 72,000 and 180,000 restricted stock units on May 2, 2024.
• The grants were initially approved by the Issuer's Compensation and Human Capital Committee on March 11, 2024, and October 11, 2023, respectively, and were subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which was obtained on May 2, 2024.
• The 72,000 restricted stock units vest in three equal annual installments beginning on March 11, 2025.
• The 180,000 restricted stock units vest 100% on October 11, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is generally seen as a positive sign, aligning management interests with shareholders. The vesting schedule suggests a long-term commitment.

Positives

• The grants of restricted stock units to a key executive like Tomas Orozco could incentivize performance and align his interests with those of shareholders.

Future Outlook

The vesting schedules for the restricted stock units suggest a long-term commitment from the executive and alignment with the company's future performance.

Industry Context

Equity grants are a common practice in the healthcare industry to attract and retain top talent and align their interests with shareholder value.

Comparison to Industry Standards

• Comparing the vesting schedules and grant sizes to similar companies in the healthcare sector would provide a benchmark for assessing the competitiveness of NeueHealth's compensation practices.
• Companies like UnitedHealth Group (UHG), CVS Health, and Humana also utilize equity grants as part of their executive compensation packages.
• Analyzing the ratio of equity compensation to total compensation for executives at these companies could offer valuable insights.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates